| [1] |
Siegel RL,Miller KD,Jemal A. Cancer statistics, 2017[J]. CA Cancer J Clin, 2017, 67(1): 7-30.
|
| [2] |
Fan L,Strasser-Weippl K,Li JJ, et al. Breast cancer in China[J]. Lancet Oncol, 2014, 15(7): e279-e289.
|
| [3] |
Ferlay J,Soerjomataram I,Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012[J]. Int J Cancer, 2015, 136(5): E359-E386.
|
| [4] |
Moorcraft SY,Gonzalez D,Walker BA. Understanding next generation sequencing in oncology: A guide for oncologists[J]. Crit Rev Oncol Hematol, 2015, 96(3): 463-474.
|
| [5] |
Stephens PJ,Tarpey PS,Davies H, et al. The landscape of cancer genes and mutational processes in breast cancer[J]. Nature, 2012, 486(7403): 400-404.
|
| [6] |
Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours[J]. Nature, 2012, 490(7418): 61-70.
|
| [7] |
Banerji S,Cibulskis K,Rangel-Escareno C, et al. Sequence analysis of mutations and translocations across breast cancer subtypes[J]. Nature, 2012, 486(7403): 405-409.
|
| [8] |
Nik-Zainal S,Davies H,Staaf J, et al. Landscape of somatic mutations in 560 breast cancer whole-genome sequences[J]. Nature, 2016, 534(7605): 47-54.
|
| [9] |
Curtis C,Shah SP,Chin SF, et al. The genomic and transcriptomic architecture of 2，000 breast tumours reveals novel subgroups[J]. Nature, 2012，486(7403): 346-352.
|
| [10] |
Yoshida K,Miki Y. Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage[J]. Cancer Sci, 2004, 95(11): 866-871.
|
| [11] |
《BRCA数据解读中国专家共识》编写组. BRCA数据解读中国专家共识[J]. 中华病理学杂志，2017, 46(5)：293-297.
|
| [12] |
D’Argenio V,Esposito MV,Telese A, et al. The molecular analysis of BRCA1 and BRCA2: Next-generation sequencing supersedes conventional approaches[J]. Clin Chim Acta, 2015, 446: 221-225.
|
| [13] |
Economopoulou P,Dimitriadis G,Psyrri A. Beyond BRCA: new hereditary breast cancer susceptibility genes[J]. Cancer Treat Rev, 2015, 41(1): 1-8.
|
| [14] |
Sun J,Meng H,Yao L, et al. Germline mutations in cancer susceptibility genes in a large series of unselected breast cancer patients[J]. Clin Cancer Res, 2017, 23(20): 6113-6119.
|
| [15] |
Goldhirsch A,Wood WC,Coates AS, et al. Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011[J]. Ann Oncol, 2011, 22(8): 1736-1747.
|
| [16] |
Goldhirsch A,Winer EP,Coates AS, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013[J]. Ann Oncol, 2013, 24(9): 2206-2223.
|
| [17] |
Coates AS,Winer EP,Goldhirsch A, et al. Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015[J]. Ann Oncol, 2015, 26(8): 1533-1546.
|
| [18] |
Curigliano G,Burstein HJ,Winer EP, et al. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017[J]. Ann Oncol, 2017, 28(8): 1700-1712.
|
| [19] |
Jeselsohn R,Buchwalter G,De Angelis C, et al. ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer[J]. Nat Rev Clin Oncol, 2015, 12(10): 573-583.
|
| [20] |
Toy W,Shen Y,Won H, et al. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer[J]. Nat Genet, 2013, 45(12): 1439-1445.
|
| [21] |
Robinson DR,Wu YM,Vats P, et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer[J]. Nat Genet, 2013, 45(12): 1446-1451.
|
| [22] |
Ellis MJ,Ding L,Shen D, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition[J]. Nature, 2012, 486(7403): 353-360.
|
| [23] |
Wong H,Leung R,Kwong A, et al. Integrating molecular mechanisms and clinical evidence in the management of trastuzumab resistant or refractory HER-2＋ metastatic breast cancer[J]. Oncologist, 2011, 16(11): 1535-1546.
|
| [24] |
Pogue-Geile KL,Song N,Jeong JH, et al. Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial[J]. J Clin Oncol, 2015, 33(12): 1340-1347.
|
| [25] |
Foulkes WD,Smith IE,Reis-Filho JS. Triple-negative breast cancer[J]. N Engl J Med, 2010, 363(20): 1938-1948.
|
| [26] |
Shah SP,Roth A,Goya R, et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers[J]. Nature, 2012, 486(7403): 395-399.
|
| [27] |
Lehmann BD,Bauer JA,Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies[J]. J Clin Invest, 2011, 121(7): 2750-2767.
|
| [28] |
Telli ML,Jensen KC,Vinayak S, et al. Phase Ⅱ study of gemcitabine, carboplatin, and iniparib as neoadjuvant therapy for triple-negative and BRCA1/2 mutation-associated breast cancer with assessment of a tumor-cased measure of genomic instability: PrECOG 0105[J]. J Clin Oncol, 2015, 33(17): 1895-1901.
|
| [29] |
Jiang YZ,Yu KD,Peng WT, et al. Enriched variations in TEKT4 and breast cancer resistance to paclitaxel[J]. Nat Commun, 2014, 5: 3802.
|
| [30] |
Craig DW,O’Shaughnessy JA,Kiefer JA, et al. Genome and transcriptome sequencing in prospective metastatic triple-negative breast cancer uncovers therapeutic vulnerabilities[J]. Mol Cancer Ther, 2013, 12(1): 104-116.
|
| [31] |
Diaz LA,Bardelli A. Liquid biopsies: genotyping circulating tumor DNA[J]. J Clin Oncol, 2014, 32(6): 579-586.
|
| [32] |
Dawson SJ,Tsui DW,Murtaza M, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer[J]. N Engl J Med, 2013, 368(13): 1199-1209.
|
| [33] |
Ma F,Zhu W,Guan Y, et al. ctDNA dynamics: a novel indicator to track resistance in metastatic breast cancer treated with anti-HER2 therapy[J]. Oncotarget, 2016, 7(40): 66 020-66 031.
|
| [34] |
Garcia-Murillas I,Schiavon G,Weigelt B, et al. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer[J]. Sci Transl Med, 2015, 7(302): 302ra133.
|
| [35] |
Olsson E,Winter C,George A, et al. Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease[J]. EMBO Mol Med, 2015, 7(8): 1034-1047.
|